Open Access
Open access
ACS Infectious Diseases, volume 5, issue 4, pages 570-581

Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase

Gibson Elizabeth G
Bax B. 1
CHAN PAN F. 2
Osheroff Neil 3
1
 
Medicines Discovery Institute, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, United Kingdom
2
 
Infectious Diseases Discovery, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
3
 
VA Tennessee Valley Healthcare System, 1310 24th Avenue S., Nashville, Tennessee 37212, United States
Publication typeJournal Article
Publication date2019-02-13
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor5.3
ISSN23738227
Infectious Diseases
Abstract
Gepotidacin is a first-in-class triazaacenaphthylene novel bacterial topoisomerase inhibitor (NBTI). The compound has successfully completed phase II trials for the treatment of acute bacterial skin/skin structure infections and for the treatment of uncomplicated urogenital gonorrhea. It also displays robust in vitro activity against a range of wild-type and fluoroquinolone-resistant bacteria. Due to the clinical promise of gepotidacin, a detailed understanding of its interactions with its antibacterial targets is essential. Thus, we characterized the mechanism of action of gepotidacin against Staphylococcus aureus gyrase. Gepotidacin was a potent inhibitor of gyrase-catalyzed DNA supercoiling (IC50 ≈ 0.047 μM) and relaxation of positively supercoiled substrates (IC50 ≈ 0.6 μM). Unlike fluoroquinolones, which induce primarily double-stranded DNA breaks, gepotidacin induced high levels of gyrase-mediated single-stranded breaks. No double-stranded breaks were observed even at high gepotidacin concentration, long cleavage times, or in the presence of ATP. Moreover, gepotidacin suppressed the formation of double-stranded breaks. Gepotidacin formed gyrase-DNA cleavage complexes that were stable for >4 h. In vitro competition suggests that gyrase binding by gepotidacin and fluoroquinolones are mutually exclusive. Finally, we determined crystal structures of gepotidacin with the S. aureus gyrase core fusion truncate with nicked (2.31 Å resolution) or intact (uncleaved) DNA (2.37 Å resolution). In both cases, a single gepotidacin molecule was bound midway between the two scissile DNA bonds and in a pocket between the two GyrA subunits. A comparison of the two structures demonstrates conformational flexibility within the central linker of gepotidacin, which may contribute to the activity of the compound.

Citations by journals

2
4
6
8
10
12
14
16
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, 15, 15.31%
Antimicrobial Agents and Chemotherapy
15 publications, 15.31%
International Journal of Molecular Sciences
International Journal of Molecular Sciences, 5, 5.1%
International Journal of Molecular Sciences
5 publications, 5.1%
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry, 5, 5.1%
Journal of Medicinal Chemistry
5 publications, 5.1%
ACS Medicinal Chemistry Letters
ACS Medicinal Chemistry Letters, 5, 5.1%
ACS Medicinal Chemistry Letters
5 publications, 5.1%
Diagnostic Microbiology and Infectious Disease
Diagnostic Microbiology and Infectious Disease, 4, 4.08%
Diagnostic Microbiology and Infectious Disease
4 publications, 4.08%
European Journal of Medicinal Chemistry
European Journal of Medicinal Chemistry, 4, 4.08%
European Journal of Medicinal Chemistry
4 publications, 4.08%
ACS Infectious Diseases
ACS Infectious Diseases, 3, 3.06%
ACS Infectious Diseases
3 publications, 3.06%
Nature Communications
Nature Communications, 3, 3.06%
Nature Communications
3 publications, 3.06%
Antibiotics
Antibiotics, 3, 3.06%
Antibiotics
3 publications, 3.06%
Molecules
Molecules, 2, 2.04%
Molecules
2 publications, 2.04%
Infectious Diseases and Therapy
Infectious Diseases and Therapy, 2, 2.04%
Infectious Diseases and Therapy
2 publications, 2.04%
Bioorganic and Medicinal Chemistry Letters
Bioorganic and Medicinal Chemistry Letters, 2, 2.04%
Bioorganic and Medicinal Chemistry Letters
2 publications, 2.04%
Journal of Molecular Structure
Journal of Molecular Structure, 2, 2.04%
Journal of Molecular Structure
2 publications, 2.04%
Clinical and Translational Science
Clinical and Translational Science, 2, 2.04%
Clinical and Translational Science
2 publications, 2.04%
Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, 2, 2.04%
Journal of Antimicrobial Chemotherapy
2 publications, 2.04%
Microbiology spectrum
Microbiology spectrum, 2, 2.04%
Microbiology spectrum
2 publications, 2.04%
ChemistrySelect
ChemistrySelect, 1, 1.02%
ChemistrySelect
1 publication, 1.02%
Mini-Reviews in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry, 1, 1.02%
Mini-Reviews in Medicinal Chemistry
1 publication, 1.02%
Current Opinion in Infectious Diseases
Current Opinion in Infectious Diseases, 1, 1.02%
Current Opinion in Infectious Diseases
1 publication, 1.02%
Sexually Transmitted Diseases
Sexually Transmitted Diseases, 1, 1.02%
Sexually Transmitted Diseases
1 publication, 1.02%
Scientia Pharmaceutica
Scientia Pharmaceutica, 1, 1.02%
Scientia Pharmaceutica
1 publication, 1.02%
Journal of Antibiotics
Journal of Antibiotics, 1, 1.02%
Journal of Antibiotics
1 publication, 1.02%
Molecular Diversity
Molecular Diversity, 1, 1.02%
Molecular Diversity
1 publication, 1.02%
Nucleic Acids Research
Nucleic Acids Research, 1, 1.02%
Nucleic Acids Research
1 publication, 1.02%
Bioorganic Chemistry
Bioorganic Chemistry, 1, 1.02%
Bioorganic Chemistry
1 publication, 1.02%
Cell Chemical Biology
Cell Chemical Biology, 1, 1.02%
Cell Chemical Biology
1 publication, 1.02%
SSRN Electronic Journal
SSRN Electronic Journal, 1, 1.02%
SSRN Electronic Journal
1 publication, 1.02%
Journal of Biological Chemistry
Journal of Biological Chemistry, 1, 1.02%
Journal of Biological Chemistry
1 publication, 1.02%
Drug Discovery Today
Drug Discovery Today, 1, 1.02%
Drug Discovery Today
1 publication, 1.02%
2
4
6
8
10
12
14
16

Citations by publishers

2
4
6
8
10
12
14
16
18
American Society for Microbiology
American Society for Microbiology, 17, 17.35%
American Society for Microbiology
17 publications, 17.35%
Elsevier
Elsevier, 17, 17.35%
Elsevier
17 publications, 17.35%
American Chemical Society (ACS)
American Chemical Society (ACS), 14, 14.29%
American Chemical Society (ACS)
14 publications, 14.29%
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 13, 13.27%
Multidisciplinary Digital Publishing Institute (MDPI)
13 publications, 13.27%
Springer Nature
Springer Nature, 8, 8.16%
Springer Nature
8 publications, 8.16%
Wiley
Wiley, 5, 5.1%
Wiley
5 publications, 5.1%
Oxford University Press
Oxford University Press, 4, 4.08%
Oxford University Press
4 publications, 4.08%
Taylor & Francis
Taylor & Francis, 4, 4.08%
Taylor & Francis
4 publications, 4.08%
Wolters Kluwer Health
Wolters Kluwer Health, 2, 2.04%
Wolters Kluwer Health
2 publications, 2.04%
Bentham Science
Bentham Science, 1, 1.02%
Bentham Science
1 publication, 1.02%
Social Science Electronic Publishing
Social Science Electronic Publishing, 1, 1.02%
Social Science Electronic Publishing
1 publication, 1.02%
American Society for Biochemistry and Molecular Biology
American Society for Biochemistry and Molecular Biology, 1, 1.02%
American Society for Biochemistry and Molecular Biology
1 publication, 1.02%
Royal Society of Chemistry (RSC)
Royal Society of Chemistry (RSC), 1, 1.02%
Royal Society of Chemistry (RSC)
1 publication, 1.02%
EMBO press
EMBO press, 1, 1.02%
EMBO press
1 publication, 1.02%
BMJ
BMJ, 1, 1.02%
BMJ
1 publication, 1.02%
American Association for the Advancement of Science (AAAS)
American Association for the Advancement of Science (AAAS), 1, 1.02%
American Association for the Advancement of Science (AAAS)
1 publication, 1.02%
European Journal of Chemistry, 1, 1.02%
European Journal of Chemistry
1 publication, 1.02%
2
4
6
8
10
12
14
16
18
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Gibson E. G. et al. Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase // ACS Infectious Diseases. 2019. Vol. 5. No. 4. pp. 570-581.
GOST all authors (up to 50) Copy
Gibson E. G., Bax B., CHAN P. F., Osheroff N. Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase // ACS Infectious Diseases. 2019. Vol. 5. No. 4. pp. 570-581.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1021/acsinfecdis.8b00315
UR - https://doi.org/10.1021%2Facsinfecdis.8b00315
TI - Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase
T2 - ACS Infectious Diseases
AU - CHAN, PAN F.
AU - Gibson, Elizabeth G
AU - Bax, B.
AU - Osheroff, Neil
PY - 2019
DA - 2019/02/13 00:00:00
PB - American Chemical Society (ACS)
SP - 570-581
IS - 4
VL - 5
PMID - 30757898
SN - 2373-8227
ER -
BibTex |
Cite this
BibTex Copy
@article{2019_Gibson,
author = {PAN F. CHAN and Elizabeth G Gibson and B. Bax and Neil Osheroff},
title = {Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase},
journal = {ACS Infectious Diseases},
year = {2019},
volume = {5},
publisher = {American Chemical Society (ACS)},
month = {feb},
url = {https://doi.org/10.1021%2Facsinfecdis.8b00315},
number = {4},
pages = {570--581},
doi = {10.1021/acsinfecdis.8b00315}
}
MLA
Cite this
MLA Copy
Gibson, Elizabeth G., et al. “Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase.” ACS Infectious Diseases, vol. 5, no. 4, Feb. 2019, pp. 570-581. https://doi.org/10.1021%2Facsinfecdis.8b00315.
Found error?